Background/Aims: Chemoresistance has been a major obstacle to the effective treatment of lung cancer. Previously, we found that contactin-1 (CNTN-1) is related to cisplatin resistance in lung adenocarcinoma. Here, we aimed to investigate the underlying mechanism behind the role of CNTN-1 in cisplatin resistance in lung adenocarcinoma. Methods: EMT-associated phenotypes, including alterations in cellular morphology and marker (E-cadherin, N-cadherin and Vimentin) expression, were compared between A549 cells and A549/DDP cells (a cisplatinresistant cell line of lung adenocarcinoma with abnormal CNTN-1 expression) by using realtime time PCR and Western blotting. Other methods, including CNTN-1 overexpression in A549 cells and CNTN-1 knockdown in A549/DDP cells, were also used to investigate the role of CNTN-1 in mediating the EMT phenotype and thr resulting cisplatin resistance and malignant progression of cancer cells in vitro and in vivo. Results: A549/DDP cells exhibited an EMT phenotype and aggravated malignant behaviors. CNTN-1 knockdown in A549/DDP cells partly reversed the EMT phenotype, increased drug sensitivity, and attenuated the malignant progression whereas CNTN-1 overexpression in A549 cells resulted in the opposite trend. Furthermore, the PI3K/Akt pathway was involved in the effects of CNTN-1 on EMT progression Conclusion: CNTN-1 promotes cisplatin resistance in human cisplatin-resistant lung adenocarcinoma through inducing the EMT process by activating the PI3K/Akt signaling pathway. CNTN-1 may be a potential therapeutic target to reverse chemoresistance in cisplatin-resistant lung adenocarcinoma.
CNTN-1 Enhances Chemoresistance in

Anoikis resistance assay
rie ly, after 5 10 5 cells were seeded in a 6-well plate coated with 12 mg/mL poly-2-hydroxyethyl methacrylate (poly-HEM , Sigma) to prevent cell attachment and suspension-cultured for 48 hrs, the cell clones suspended in the medium were captured under a light microscope (Olympus 51, apan) and harvested to examine the apoptotic ratio of cells by low cytometry using the annexin V-FITC/PI staining method ( eyotime, China).
Cell apoptosis analysis
fter cells were seeded in petri dishes (10-cm diameter, 3 10 4 cells per dish) and grown to 70-80% con luence, the cells were incubated with 2 g/mL cisplatin for 48 hrs and collected. Then, low cytometry assay was performed to detect apoptotic cells using the annexin V-FITC/PI staining method ( eyotime, China).
In vitro drug sensitivity assay
rie ly, after cells were incubated with different concentrations of cisplatin (10, 5, 2.5, 1.25, 0.625, and 0 ug/mL) for 48 hrs, 100 l fresh culture medium and 10 l Cell Counting Kit-8 (CCK-8) solution ( eyotime, China) were added to each well and incubated for 1 hr. Then, the absorbance value at the wavelength of 450 nm was measured. Cells incubated without cisplatin were treated as negative controls. The 50% inhibitory concentration (IC 50 ) was calculated using raphPad Prism 5.0 software.
Migration and invasion assay
The migration ability of cancer cells was evaluated by a wound-healing assay. rie ly, after cells were seeded in a 6-well plate (5 10 5 cells per well) and cultured overnight, the con luent cell monolayer was se uentially scratched in a straight line with a 200-l pipette tip, washed with sterile P S and cultured in fresh medium for 20 hrs. Migrated cells were photographed at 0 hr and 20 hrs under a light microscope (Olympus 51, apan). The cell metastasis ability in each group was calculated using Image-Pro Plus software (Version 5.1, Media Cybernetics, Inc.). The cell invasion ability was evaluated using modi ied oyden chambers with ilter inserts (pore si e of 8 m, Corning Inc., Life Science) according to our previous method [36] . Invasive cells were observed under a light microscope (Olympus 51, apan), and calculated using Image-Pro Plus software (Version 5.1, Media Cybernetics, Inc.).
RNA isolation and real-time PCR analysis
fter the total RN of cancer cells was extracted using TRI ol reagent (Invitrogen, S ) according to the manufacturer's instructions, irst-strand cDN was synthesi ed from total RN (1 ug) using a First Strand cDN Synthesis Kit (Roche). Then, real-time PCR was performed on a reaction system containing cDN , S R reen Mix (TO O O), and primers (Table 1) . lyceraldehyde-3-phosphate dehydrogenase ( PDH) was used as an internal control. The relative expression of target genes was expressed as 2 -Ct .
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Western blot analysis fter the total protein was extracted from cancer cells using RIP lysis solution ( eyotime, China), protein expression was analy ed by estern blotting assay as described previously [36] . The primary antibodies and secondary antibodies used in this experiment are listed in Table 2 . Protein bands were visuali ed using a SuperSignal est Pico Trial Kit (Thermo) and analy ed using Image software (National Institutes of Health, S ).
Xenograft tumorigenicity experiment
Healthy SCID mice (Four to ive-wee -old female, n 20) were purchased from the nimal Laboratory of in iao Hospital and housed in a climate-control SPF (Speci ic Pathogen Free) facility. The mice were divided into two groups that were subcutaneously inoculated with 549/DDP-shCNTN-1 cells and 549/ DDP-shCNTN-1-NC cells into the right lan (100 L, 1 10 6 cells per animal), respectively. Tumors were monitored on the day of tumor formation and measured every three days for a total of 48 days. Tumor volume (mm 3 ) was calculated according to the formula a b 2 /2 (a largest diameter b smallest diameter) [38] . s previously described [16] , when the tumor volume reached 150 mm 3 , one subgroup of nude mice in each group was injected with a cisplatin solution (cisplatin concentration: 10 mg per 2 mL in normal saline (NS) injection dosage: 0.2 mg cisplatin per 10 g animal weight (20 mg/ g)) via intraperitoneal injection every three days, while the other subgroup of mice was used as controls and injected with NS. fter 48 days, saline-treated xenograft tumors ( 549/DDP-shCNTN-1-NC and 549/DDP-shCNTN-1) were isolated to detect protein expression of CNTN-1 and EMT biomar ers by estern blot and immunohistochemistry, respectively. Meanwhile, the lung and liver tissues were separated to observe tumor metastasis in vivo by HE staining.
Hematoxylin and eosin (HE) staining and immunohistochemistry
Tissue samples including xenograft tumors, lung tissues, and liver tissues were se uentially ixed with 4% paraformaldehyde for 24 hrs, embedded in paraf in, and sectioned. Then, HE staining and immunostaining were performed on the 4-m-thic sections of xenograft tumors as previously described [36] . The primary and secondary antibodies used for immunohistochemistry are shown in Table 2 . dditionally, HE staining was performed on the 4-m-thic sections of liver and lung tissues to simply observe the metastasis of the xenografted tumors in vivo. ll sections were observed under a light microscope (Olympus 51, apan).
Statistical analysis ll numerical data in this study were presented as the mean SD and analy ed using SPSS 13.0 software. fter a homogeneity test for variance, the signi icant difference between two groups was analy ed using an independent-samples t test, whereas the signi icant difference between multiple groups was analy ed by one-way analysis of variance ( NOV ) followed by LSD post hoc test. p-value of less than 0.05 was regarded as statistically signi icant.
Results
Cisplatin-resistant lung adenocarcinoma cells displayed an EMT phenotype
Consistent with our previous report [36] , 549/DDP cells exhibited more resistance to cisplatin than 549 cells ( Fig. 1 ) , veri ied by the apoptosis analysis, which showed that 549/DDP cells displayed a lower percentage of apoptotic cells than 549 cells when exposed to cisplatin (Fig. 1 ) . To evaluate the association of EMT development with cisplatin resistance, EMT-related cellular morphological changes and expression of EMTrelated mar ers (E-cadherin, N-cadherin and vimentin) were compared between 549 cells and 549/DDP cells. Interestingly, 549/DDP cells displayed an elongated and irregular ibroblastic morphology with growth separately from one another, whereas 549 cells exhibited an epithelial morphology characteri ed by a round shape and growth in clusters (Fig. 1C) , veri ied by the cytos eleton F-actin staining (Fig. 1D) . Compared with that of 549 cells, both the expression of N-cadherin and vimentin (mesenchymal mar ers) was upregulated, while the expression of E-cadherin (epithelial mar er) was downregulated in 549/DDP cells both at the mRN and protein levels ( Fig. 1E-F ). These results indicate that cisplatin-resistant lung adenocarcinoma cells ac uire an EMT phenotype.
dditionally, the association of the EMT phenotype with malignant progression was also analy ed in 549/DDP and 549 cells. The wound-healing assay and transwell invasion assay showed that the migration and invasion of 549/DDP cells was signi icantly greater than that of 549 cells (Fig. 2 -) . Moreover, the anoi is resistance assay showed that 549/DDP cells formed larger cellular aggregates than 549 cells, which mainly were found as individual cells and smaller cellular aggregates (Fig. 2C ). Flow cytometry analysis of these suspended cells demonstrated that 549 cells had a higher proportion of anoi is than 549/DDP cells (Fig. 2D) . Furthermore, the expression of pluripotent mar ers (CD44, OCT-4 and Nanog) was higher in 549/DDP cells than in 549 cells (Fig. 2E) . Collectively, these indings suggest that EMT development in cisplatin-resistant lung adenocarcinoma cells aggravates tumor malignant behaviors.
CNTN-1 expression positively correlated with the EMT phenotype, cisplatin resistance, and tumor malignant progression in lung adenocarcinoma cells
Our previous studies found that CNTN-1 was signi icantly upregulated in 549/DDP cells compared with that of 549 cells [36] . To investigate whether the EMT phenotype was correlated with CNTN-1, CNTN-1 was successfully overexpressed in 549 cells ( 549-CNTN-1, Fig. 3 -) and silenced in 549/DDP cells ( 549/DDP-shCNTN-1, Fig. 3C-D) both at the gene and protein levels. Then, the expression of EMT-related mar ers was detected, and the data revealed that 549-CNTN-1 cells displayed an EMT phenotype, characteri ed by upregulated expression of mescenchymal mar ers (N-cadherin and vimentin) and downregulated expression of the epithelial mar er (E-cadherin) (Fig. 3E-F) , whereas 549/ DDP-shCNTN-1 cells had a signi icantly attenuated EMT phenotype, characteri ed by the opposite trend in EMT-related mar er expression (Fig. 3 -H) . These molecular changes were veri ied by EMT-associated morphological changes, characteri ed by an elongated and irregular mesenchymal phenotype in 549-CNTN-1 cells in contrast to an epithelial phenotype in 549-shCNTN-1 cells (Fig. 3I) . Moreover, CNTN-1 overexpression signi icantly decreased cisplatin sensitivity and apoptosis ( 549-CNTN-1 vs 549-CNTN-1-NC), while CNTN-1 silencing signi icantly increased cisplatin sensitivity and apoptosis ( 549/DDPshCNTN-1 vs 549/DDP-shCNTN-1-NC, Fig. 3 -K) .
dditionally, CNTN-1 overexpression induced the formation of large cell aggregates (Fig. 4 ) , decreased the proportion of anoi is (Fig. 4 ) , and promoted cell migration (Fig.  4C ) and invasion ( Fig. 4D ) ( 549-CNTN-1 vs. 549-CNTN-1-NC), whereas CNTN-1 silencing inhibited cell aggregate formation (Fig. 4 ) , increased the proportion of anoi is (Fig. 4 ) , and inhibited cell migration (Fig. 4C) and invasion (Fig. 4D ) ( 549/DDP-shCNTN-1 vs. 549/ DDP-shCNTN-1-NC), strongly suggesting that the EMT process is correlated with cisplatin resistance and malignant behavior in lung adenocarcinoma cells via CNTN-1. 
CNTN-1 facilitated the EMT process and resulting cisplatin resistance via activating the PI3K/Akt signaling pathway
The PI3K/ t pathway is not only a vital signal transduction pathway that regulates EMT development [39] [40] but also an ef icient target to promote drug sensitivity in some cancer cells [41] . To explore the mechanisms of CNTN-1 involvement in the EMT phenotype, cisplatin resistance, and malignant behavior in lung adenocarcinoma cells, PI3K/ t activity was analy ed and the results demonstrated that the PI3K/ t pathway was more activated in 549/DDP cells than in 549 cells, which was coincident with CNTN-1 expression (Fig.  5 ) . Moreover, p-t was signi icantly upregulated in 549-CNTN-1 cells but downregulated in 549/DDP-shCNTN-1 cells, indicating that the PI3K/ t activity was regulated by CNTN-1 (Fig. 5 ) .
ecause an inhibitor of CNTN-1 is not available presently, L 294002, an inhibitor of PI3K/ t pathway, was used to verify the association of PI3K/ t activity with CNTN-1, the EMT phenotype, and tumor malignant behaviors of cisplatin-resistant lung adenocarcinoma cells. s shown Fig. 5C , inhibition of the PI3K/ t pathway had no in luence on CNTN-1 expression, con irming that CNTN-1 is an upstream molecule regulating the PI3K/ t signaling pathway. dditionally, when the PI3K/ t pathway was inhibited, the mesenchymalli e cellular morphology was reversed (Fig. 5D) , and epithelial mar er (E-cadherin) expression was signi icantly upregulated, whereas the expression of mesenchymal mar ers (N-cadherin and vimentin) was signi icantly downregulated ( 549/DDP-L 294002 vs. 549/DDP) (Fig. 5E) . Moreover, inhibitor L 294002 increased the sensitivity of 549/DDP cells to cisplatin (Fig. 5F ) and attenuated cell metastasis and invasion (Fig. 5 -H ). These indings suggest that CNTN-1 participates in the EMT process which leads to malignant progression in lung adenocarcinoma cells via activating the PI3K/ t pathway.
Knockdown of CNTN-1 reversed cisplatin resistance and the EMT phenotype of A549/DDP cells in vivo
To investigate the potential of CNTN-1 to reverse the EMT phenotype and cisplatin resistance of lung adenocarcinoma cells in clinical practice, a xenograft mouse model was established. lthough no signi icant difference in the tumor volume was found between 549/DDP-shCNTN-1 and 549/DDP-shCNTN-1-NC before cisplatin supplementation (on day 30), further growth of the tumors developed with 549/DDP-shCNTN-1 was signi icantly prevented after the next 3 wee s cisplatin injection ( 549/DDP-shCNTN-1 vs. 549/DDPshCNTN-1-NC) (Fig. 6 -) . In addition, the inal tumor weight of the 549/DDP-shCNTN-1 
Discussion
Despite the numerous achievements that have been obtained in the ield of cancer therapy, platinum-based chemoresistance is still a main obstacle to the successful treatment of NSCLC [8] . Further exploration of the potential mechanisms of chemoresistance may help to address this challenge. Several recent studies reporting that CNTN-1 not only facilitates the metastasis of gastric cancer cells via activation of the EMT process [35] , but also promotes drug resistance of lung adenocarcinoma [36] suggested that CNTN-1 might be a potential therapeutic target to inhibit malignant behaviors via mediating the EMT process in cisplatinresistant lung adenocarcinoma cells. To test this hypothesis, we carried out this study, and the indings demonstrated for the irst time that CNTN-1 downregulation could inhibit cisplatin resistance and malignant progression via partly inactivating the EMT process by regulating the PI3K/ t pathway, suggesting that CNTN-1 may be a potential target to reverse the malignant behaviors and improve chemotherapeutic ef iciency in cisplatin-resistant lung adenocarcinoma.
CNTN-1 is an important molecule in nervous system development and maintenance [42] . Recently, CNTN-1 was demonstrated to be able to promote invasion, metastasis and proliferation in prostate cancer [43] , thyroid cancer [44] , gastric cancer [35, [45] [46] , lung cancer [32] [33] , esophageal s uamous cancer [30, 47] , and oral s uamous cancer [31] . dditionally, in our previous studies, CNTN-1 was found to enhance the metastasis, invasion, and chemoresistance of lung cancer cells [36] . ased on these indings, we carried out a meta-analysis study that suggested that CNTN-1 might be a potential biomar er for tumor progression in carcinomas [48] . However, the mechanism behind the effects of CNTN-1 on cisplatin resistance in lung adenocarcinoma remains unclear.
EMT development is associated with an increase in migration, invasion, and anoi is tolerance in many malignancies [35, [49] [50] [51] . Moreover, EMT progression has been regarded as a novel mechanism for drug resistance in epithelial-originated malignancies [12] [13] [14] 40] . To test our hypothesis, irst, the EMT phenotype was compared between 549/DDP cells and their progenitor 549 cells to evaluate the association of EMT development with cisplatin resistance. The results revealed that 549/DDP cells displayed an elongated and irregular ibroblastic morphology, while 549 cells exhibited an epithelial morphology characteri ed by a round shape and cluster growth (Fig. 1C) and veri ied by cytos eleton F-actin staining (Fig. 1D ) and the detection of EMT-related mar ers (Fig. 1E-F) , indicating that the EMT phenotype was correlated with the cisplatin resistance of lung adenocarcinoma.
dditionally, the EMT phenotype promoted the malignant progression in cisplatin-resistant lung adenocarcinoma cells, re lected by the observation that the migration (Fig. 2 ) , invasion (Fig. 2 ) , and anoi is resistance (Fig. 2C-D) of 549/DDP cells were signi icantly greater than 549 cells. Moreover, pluripotent mar ers (CD44, OCT-4, and Nanog) were upregulated in 549/DDP cells compared with those in 549 cells (Fig. 2E) . Collectively, these indings suggest that cisplatin-resistant lung adenocarcinoma cells with an EMT phenotype display aggravated tumor malignant behaviors.
To The PI3K/ t signaling pathway is a ey pathway that regulates the EMT process, cell proliferation, survival, migration, and invasion [39] [40] . ctivation of the t signaling pathway has not only been reported to be involved in T F--induced EMT development [52] , but also in increasing snail expression and inducing EMT development through phosphorylation of IKK [52] . Moreover, activation of t signaling is also related with the chemoresistance of tumor cells [53] [54] . In this study, p-t was signi icantly higher in 549/DDP cells than in 549 cells, which was reversed by CNTN-1 silencing, suggesting that CNTN-1 is the upstream molecule regulating the PI3K/ t signaling pathway. ecause noc down of p-t is hard to achieve, a speci ic inhibitor, L 294002, was used to investigate the role of the PI3K/ t pathway in this study. e found that when the PI3K/ t pathway in 549/DDP cells was inhibited by L 294002, the EMT phenotype was partly reversed, and the malignant behaviors were attenuated, strongly suggesting that the PI3K/ t signaling pathway is a crucial pathway that regulates the EMT process and the malignant progression of lung adenocarcinoma, which is partly mediated by CNTN-1.
ecause the study was aimed to investigate whether the PI3K/ t pathway is involved in the CNTN-1-mediated EMT process and the resulting cisplatin resistance in 549/DDP cells, we did not explore how CNTN-1 activates the PI3K/ t pathway in this study. However, prior studies have provided us two main potential mechanisms. One of which is that CNTN-1 enhances KT activation in part by preventing PHLPP2-mediated KT dephosphorylation [33] . The other is that CNTN-1 can bind to the receptor protein tyrosine phosphatases gamma eta (PTPR ) through its structural C domains [55] , given that CNTN-1 has six Ig domains, four ibronectin-li e motifs, and a glycosyl phosphatidylinositol ( PI) moiety [28] . To clearly understand this process, further studies are needed in the future.
To evaluate the potential of CNTN-1 to reverse the EMT phenotype and cisplatin resistance of lung adenocarcinoma cells in clinical practice, a xenograft mouse model was established, and the data revealed that along the course of the experiment, further growth of the 549/DDP-shCNTN-1 tumors treated with DDP was signi icantly prevented compared with that of 549/DDP-shCNTN-1 tumors treated with saline and that of 549/DDP-shCNTN-1-NC tumors treated with DDP and saline. dditionally, consistent with the previous studies that showed that CNTN-1 silencing dramatically increased cisplatin sensitivity without affecting cell proliferation [34, 36] , no signi icant difference in the si es of the saline-treated 549/DDP-shCNTN-1 tumors and the saline-treated 549/DDP-shCNTN-1-NC tumors was detected in the animal model, suggesting that CNTN-1 contributes to the cisplatin resistance rather than tumor growth of lung adenocarcinoma cells (Fig. 6 -C) . dditionally, the indings that the tumors developed with 549/DDP-shCNTN-1 cells grew very slowly after cisplatin treatment revealed that although CNTN-1 contributes to the cisplatin resistance of 549/ DDP cells, other genes might also be involved in the cisplatin resistance of 549/DDP cells. Moreover, the results showed that mesenchymal mar er (N-cadherin) expression was lower, whereas expression of epithelial mar er (E-cadherin) was higher in 549/DDP-shCNTN-1-saline tumors than in 549/DDP-shCNTN-1-NC-saline tumors (Fig. 6E-F) . Furthermore, HE staining showed a reversal of the EMT-related cellular morphology in 549/DDPshCNTN-1 tumors (Fig. 6 ) . These results further con irm that CNTN-1 contributes to the EMT phenotype in cisplatin-resistant lung adenocarcinoma cells.
lthough we report for the irst time that CNTN-1 contributed to the EMT phenotype and resulting cisplatin resistace and malignant progression of lung adenocarcinoma, some limitations still exist in our research. First, we were unable to evaluate the role of CNTN-1 in patients with lung adenocarcinoma due to the dif iculties in collecting ade uate cisplatinresistant samples in clinical practice to verify the indings of the CNTN-1 modulation of the EMT process, cisplatin resistance, and tumor malignant behaviors obtained from the cell model and animal model. Second, the mouse model of the study was only done with a resistant cell line. Furthermore, although short-term cisplatin treatment was shown to prevent further growth of 549/DDP-shCNTN-1-DDP tumors, whether long-term cisplatin treatment has the same effects re uires further investigation. Third, although the experiments of CNTN-1 overexpression in 549 cells and CNTN-1 noc down in 549/DDP cells indicated a positive role of CNTN-1 in promoting cisplatin resistance, increasing the level of CNTN-1 expression in 549/DDP cells was not performed, but this additional experiment may further bac up our conclusion.
In conclusion, the present study showed that CNTN-1 upregulation promotes the malignant progression (including metastasis, invasion, and drug resistance) of cisplatinresistant lung adenocarcinoma cells through inducing an EMT phenotype by activating the PI3K/ t signaling pathway, which strongly suggests that CNTN-1 may be a potential therapeutic target to reverse the malignant progression in cisplatin-resistant lung adenocarcinoma cells.
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